Table 2.
Clinical trials testing combined targeting of ICRs.
| ICI combinations | Agents | Company | Clinical trials | Cancer types |
|---|---|---|---|---|
| CTLA4 + PD-1/PD-L1 | Ipilimumab+ Nivolumab | Bristol-Myers Squibb | FDA approval | HCC, pleural mesothelioma, metastatic melanoma, colon cancer, urothelial cancer, metastatic NSCLC, RCC |
| Ipilimumab+ Nivolumab | Bristol-Myers Squibb | NCT04080804 NCT04606316 | HNSCC Glioblastoma Results: recruiting |
|
| Ipilimumab+ Pembrolizumab | Merck Sharp & Dohme |
NCT02089685 NCT03302234 NCT03873818 |
Metastatic melanoma, RCC Results: showed tolerability and antitumor activity NSCLC Results: combination therapy failed to improve efficacy over monotherapy. Metastatic melanoma (recruiting) |
|
| VISTA + PD-1/PD-L1 | CA170 (dual activity) | Curis | NCT02812875 CTRI/2017/12/011026 | Hodgkin lymphoma, NSCLC No results |
| HMBD-002 + Pembrolizumab | Hummingbird | NCT05082610 | Advanced solid tumors, TNBC, NSCLC No results |
|
| W0180 + Pembrolizumab | Pierre Fabre | NCT04564417 | Locally advanced or metastatic solid tumors, No results |
|
| KVA12123 + pembrolizumab | Kineta | NCT05708950 | Advanced solid tumors, Recruiting |
|
| TIGIT + PD-1/PD-L1 | Tiragolumab + Atezolizumab | Roche | NCT03563716 | Metastatic NSCLC Results: show improved ORR and PFS |
| Vibostolimab (MK-7684) + Pembrolizumab | Merck Sharp & Dohme |
NCT02964013 NCT04725188 NCT04738487 NCT05665595 NCT02625961 NCT05298423 NCT05845814 |
Advanced solid tumors, including NSCLC, melanoma, bladder cancer, urothelial carcinoma Results: recruiting |
|
| BMS-986207 + Nivolumab+ Ipilimumab | Bristol-Myers Squibb | NCT05005273 | NSCLC Results: terminated |
|
| BMS-986207 + Nivolumab+ COM701 (anti- PVRIG) | Bristol-Myers Squibb | NCT04570839 | Advance solid tumors No results |
|
| ASP8374 + Pembrolizumab | Astellas | NCT03260322 NCT04826393 | Advance solid tumors Recurrent glioma No results |
|
| Domvanalimab (AB154) + Zimberelimab (AB122, anti-PD-1) | Arcus Bioscience | NCT04262856 | Metastatic NSCLC Results: improved ORR and PFS in combination therapy. |
|
| BGB-A1217 + Tislelizumab (anti-PD-1) | Beigene | NCT04047862 | metastatic squamous NSCLC Results: recruiting |
|
| Etigilimab + Nivolumab | Mereo BioPharma | NCT04761198 | Advanced solid tumors, cervical cancer, uveal melanoma, ovarian cancer, NSCLC. Results: showed early efficacy |
|
| TIM3 + PD-1/PD-L1 | Cobolimab (TSR-022) + Nivolumab or TSR-042 (anti-PD-1) | Tesaro |
NCT02817633 NCT03680508 |
Advanced solid tumors such as NSCLC, melanoma, HCC, Results: showed clinical efficacy |
| Sabatolimab (MBG453) + Spartalizumab (PDR001, anti-PD-1) | Novartis | NCT02608268 | Advanced solid cancers such as melanoma and NSCLC Results: preliminary antitumor activity |
|
| Sym023 + Sym-021 (anti-PD-1) | Symphogen | NCT03311412 | Advanced solid tumors, lymphomas, No results. |
|
| LY3321367 + LY3300054 (Anti-PD-L1) | Eli Lilly | NCT03099109 | Advanced solid tumors, Results: modest antitumor activity. |
|
| BMS986258 + Nivolumab | Bristol-Myers Squibb | NCT03446040 | Advanced solid tumors, Recruiting |
|
| LAG3 + PD-1/PD-L1 | Relatlimab + Nivolumab | Bristol-Myers Squibb | FDA approval | Unresectable or metastatic melanoma |
| Favezelimab (MK-4280) + Pembrolizumab | Merck Sharp & Dohme |
NCT02720068 NCT03598608 NCT05064059 |
Colorectal cancer, Lymphomas, Recruiting |
|
| Ieramilimab + Spartalizumab (PDR001, anti-PD-1) | Novartis | NCT02460224 | Advanced solid tumors, melanoma, TNBCs, mesothelioma, Results: modest antitumor activity |
|
| Fianlimab + Cemiplimab (anti-PD-1) | Regeneron | NCT03005782 | Advanced melanoma, Results: preliminary antitumor activity, ongoing biomarker analysis |
|
| Eftilagimod alpha + Pembrolizumab | Immutep | NCT03625323 | Metastatic NSCLC and HNSCC, Results: showed antitumor activity |
|
| Encelimab (TSR-033) + Dostarlimab (TSR-042, anti-PD-1) | Tesaro | NCT03250832 | Advanced solid tumors, No results. |
|
| BI-754111 + BI-754091 (anti-PD-1) | Boehringer Ingelheim | NCT03156114 NCT03433898 NCT03697304 NCT03780725 | Advanced solid tumors, NSCLC, Results: manageable safety profile but no improved antitumor activity |
|
| Sym-022 + Sym-021 (anti-PD-1) | Symphogen |
NCT03311412 NCT03489369 NCT03489343 |
Advanced solid tumors, lymphomas, Results: preliminary antitumor activity |
|
| LAG3 + TIM3 +PD-1 | INCAGN02385 (anti-LAG3) + INCAGN2390 (anti-TIM3) + Retifanlimab (INCMGA00012, Anti–PD-1) |
Incyte | NCT04370704 | Advanced solid tumors Results: recruiting |